GILD – Gilead Sciences Inc. – Fundamental analysis, financial statements, key ratios, and fair value analysis

Gilead Sciences Inc.

Healthcare
Biotechnology
68.25
3
4.60%
88.8
60.54
Stock Current Price
Change
Change %
52 Week High
52 Week Low

Financial Ratios

Earnings per Share (EPS)1.21
EPS Estimate Currrent Qtr1.63
Book Value Per Share17.67
Market Cap 88 Billion
PE Ratio 51.4
Dividend Yield3.6064537

Stock Yield

Stock Return 7 Days2.21%
Stock Return 15 Days-4.98%
Stock Return 30 Days -12.67%
Stock Return 3 Months-21.34%
Stock Return One Year-15.89%
Stock Return 3 Years-14.98%

Stock Technical Analysis

Relative Strengh Index (14)40.49
Average True Range (14)2.49
Momentum (14)-2.89
Simple Moving Average (14) -2.89
Time Series Forecast (14)60.7
Time Series Forecast (30) 70.26

Stock News

NewsSourcePublished
Better Buy: Gilead Sciences vs. AmgenYahoo Finance01/06/2019 23:06
Gilead Sciences and Yuhan Corporation Announce Collaboration and License Agreement to Develop Novel Investigational Treatments for Advanced Fibrosis Due to Nonalcoholic SteatohepatitisYahoo Finance01/06/2019 22:30
2019 J.P. Morgan Healthcare Conference RoundupYahoo Finance01/06/2019 16:00
See what the IHS Markit Score report has to say about Gilead Sciences Inc.Yahoo Finance01/05/2019 13:06
Biotechs lead broad market advance, XBI up 5%Seeking Alpha01/04/2019 13:11
Today’s Research Reports on Trending Tickers: Prana Biotechnology and Gilead SciencesYahoo Finance01/04/2019 11:50
Factbox – Bristol-Myers’ $74 billion Celgene buy has investors looking for next dealYahoo Finance01/03/2019 22:46
Gilead Stock Breaks Out to Channel ResistanceYahoo Finance01/03/2019 19:35
Needham sees 27% upside in Thermo Fisher in today’s analyst actionSeeking Alpha01/03/2019 13:43
3 Biopharma Stocks to Buy for Their Robust Dividend YieldsYahoo Finance01/03/2019 17:35
Gilead Sciences Gets a Boost After Celgene DealYahoo Finance01/03/2019 15:51
Gilead Sciences: Top Biotech Pick For The Next Decade With An Options PlaySeeking Alpha01/03/2019 09:43
Stocks Tumble, Celgene Spikes; Apple Cripples Global Tech StocksYahoo Finance01/03/2019 13:51
BMY/Celgene tie-up buoys Gilead and Vertex premarketSeeking Alpha01/03/2019 07:51
Drug makers OK with price inclusion in TV ads if done fairlySeeking Alpha01/02/2019 11:34
Gilead Sciences to Present at the 37th Annual J.P. Morgan Healthcare Conference on Monday, January 7Yahoo Finance01/02/2019 14:01
Biotech Rally Ahead of the MarketYahoo Finance01/02/2019 13:30
CNBC article highlights $35B market opportunity of NASH drugsSeeking Alpha12/31/2018 11:59
The $35 billion race to cure a liver disease that affects 30 million AmericansYahoo Finance12/30/2018 13:39

Financial Statements

index2014201520162017
Revenue25 Billion33 Billion30 Billion26 Billion
Cost of Revenue4 Billion4 Billion4 Billion4 Billion
Gross Profit21 Billion29 Billion26 Billion22 Billion
Gross Margin (%)84.78%87.73%85.98%83.26%
Selling General and Administrative Expense3 Billion3 Billion3 Billion4 Billion
Other operating expenses3 Billion3 Billion5 Billion3 Billion
Earning Before Interest and Taxes EBIT15 Billion22 Billion18 Billion15 Billion
EBIT/Operating Margin (%)61.51%68.47%59.47%56.04%
Interest Expense412 Million688 Million964 Million1 Billion
Other non-operating expenses/income0000
Earnings before Tax15 Billion22 Billion17 Billion14 Billion
Income Tax Expense3 Billion4 Billion4 Billion9 Billion
Net Income12 Billion18 Billion14 Billion5 Billion
Net Margin (%)48.62%55.48%44.43%17.73%
Earnings per share from operating income0.1721340.1036280.134680.900686
Earnings per Diluted Share7.3511.919.943.51
Dividends per Basic Common Share01.291.842.08
Payout ratioNA9.232565.402171.6875
Weighted average number of shares outstanding2 Billion2 Billion1 Billion1 Billion
index2017 Q42018 Q12018 Q22018 Q3
Revenue6 Billion5 Billion6 Billion6 Billion
Cost of Revenue1 Billion1 Billion1 Billion1 Billion
Gross Profit5 Billion4 Billion4 Billion5 Billion
Gross Margin (%)78.89%80.33%78.82%80.59%
Selling General and Administrative Expense1 Billion997 Million980 Million948 Million
Other operating expenses1 Billion768 Million1 Billion636 Million
Earning Before Interest and Taxes EBIT2 Billion2 Billion2 Billion3 Billion
EBIT/Operating Margin (%)40.24%45.64%41.61%52.29%
Interest Expense297 Million290 Million266 Million264 Million
Other non-operating expenses/income0000
Earnings before Tax2 Billion2 Billion2 Billion3 Billion
Income Tax Expense6 Billion494 Million267 Million565 Million
Net Income-4 Billion2 Billion2 Billion2 Billion
Net Margin (%)-100.00%30.23%32.17%37.47%
Earnings per share from operating income0.2114011.290390.9304610.872079
Earnings per Diluted Share-31.171.391.6
Dividends per Basic Common Share0.520.570.570.57
Payout ratio-62.052632.43862.80702
Weighted average number of shares outstanding1 Billion1 Billion1 Billion1 Billion
index2014201520162017
Cash and Equivalents10 Billion13 Billion8 Billion8 Billion
Trade and Non Trade Receivables5 Billion6 Billion5 Billion4 Billion
Inventory1 Billion2 Billion2 Billion801 Million
Other current assets22 Billion30 Billion22 Billion35 Billion
Current Assets18 Billion25 Billion20 Billion32 Billion
Total Non-Current Assets17 Billion27 Billion37 Billion38 Billion
Total Assets35 Billion52 Billion57 Billion70 Billion
Trade and Non Trade Payables955 Million1 Billion1 Billion814 Million
Other current liabilities5 Billion9 Billion8 Billion11 Billion
Current Liabilities6 Billion10 Billion9 Billion12 Billion
Liabilities Non Current13 Billion23 Billion28 Billion38 Billion
Accumulated Retained Earnings Deficit13 Billion18 Billion18 Billion19 Billion
Shareholder’s equity other3 Billion533 Million733 Million1 Billion
Shareholders Equity15 Billion19 Billion19 Billion20 Billion
Noncontrolling interests12 Billion20 Billion19 Billion23 Billion
Total Assets35 Billion52 Billion57 Billion70 Billion
index2017 Q42018 Q12018 Q22018 Q3
Cash and Equivalents8 Billion8 Billion13 Billion15 Billion
Trade and Non Trade Receivables4 Billion4 Billion4 Billion3 Billion
Inventory801 Million885 Million859 Million816 Million
Other current assets35 Billion33 Billion42 Billion45 Billion
Current Assets32 Billion30 Billion33 Billion35 Billion
Total Non-Current Assets38 Billion35 Billion33 Billion29 Billion
Total Assets70 Billion65 Billion65 Billion64 Billion
Trade and Non Trade Payables814 Million711 Million623 Million580 Million
Other current liabilities11 Billion10 Billion10 Billion10 Billion
Current Liabilities12 Billion11 Billion11 Billion10 Billion
Liabilities Non Current38 Billion34 Billion33 Billion31 Billion
Accumulated Retained Earnings Deficit19 Billion19 Billion20 Billion21 Billion
Shareholder’s equity other1 Billion1 Billion2 Billion2 Billion
Shareholders Equity20 Billion21 Billion22 Billion23 Billion
Noncontrolling interests23 Billion21 Billion22 Billion20 Billion
Total Assets70 Billion65 Billion65 Billion64 Billion
index2014201520162017
Net Cash Flow from Operations13 Billion21 Billion17 Billion12 Billion
Capital Expenditure-557 Million-747 Million-748 Million-590 Million
Net Cash Flow from Investing-2 Billion-12 Billion-12 Billion-16 Billion
Net Cash Flow from Financing-3 Billion-6 Billion-10 Billion3 Billion
Cash and Equivalents10 Billion13 Billion8 Billion8 Billion
index2017 Q42018 Q12018 Q22018 Q3
Net Cash Flow from Operations3 Billion2 Billion2 Billion2 Billion
Capital Expenditure-220 Million-212 Million-297 Million-167 Million
Net Cash Flow from Investing-10 Billion4 Billion5 Billion2 Billion
Net Cash Flow from Financing3 Billion-7 Billion-1 Billion-3 Billion
Cash and Equivalents8 Billion8 Billion13 Billion15 Billion

Stock Price History

table